EP1320621A4 - IMPROVED ADENOVIRAL VACCINES OF THE FIRST GENERATION FOR THE EXPRESSION OF CODON-OPTIMIZED HIV-1 GAG, POL, NEF AND MODIFICATIONS (25.03.02) - Google Patents

IMPROVED ADENOVIRAL VACCINES OF THE FIRST GENERATION FOR THE EXPRESSION OF CODON-OPTIMIZED HIV-1 GAG, POL, NEF AND MODIFICATIONS (25.03.02)

Info

Publication number
EP1320621A4
EP1320621A4 EP01975214A EP01975214A EP1320621A4 EP 1320621 A4 EP1320621 A4 EP 1320621A4 EP 01975214 A EP01975214 A EP 01975214A EP 01975214 A EP01975214 A EP 01975214A EP 1320621 A4 EP1320621 A4 EP 1320621A4
Authority
EP
European Patent Office
Prior art keywords
pol
gag
hiv
advanced
changes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP01975214A
Other languages
German (de)
English (en)
French (fr)
Other versions
EP1320621A2 (en
Inventor
Emilio A Emini
Rima Youil
Andrew J Bett
Ling Chen
David C Kaslow
John W Shiver
Timothy J Toner
Danilo R Casimiro
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck and Co Inc
Original Assignee
Merck and Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck and Co Inc filed Critical Merck and Co Inc
Publication of EP1320621A2 publication Critical patent/EP1320621A2/en
Publication of EP1320621A4 publication Critical patent/EP1320621A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10351—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
    • C12N2740/16334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/42—Vector systems having a special element relevant for transcription being an intron or intervening sequence for splicing and/or stability of RNA

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Plant Pathology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
EP01975214A 2000-09-15 2001-09-14 IMPROVED ADENOVIRAL VACCINES OF THE FIRST GENERATION FOR THE EXPRESSION OF CODON-OPTIMIZED HIV-1 GAG, POL, NEF AND MODIFICATIONS (25.03.02) Withdrawn EP1320621A4 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US23318000P 2000-09-15 2000-09-15
US233180P 2000-09-15
PCT/US2001/028861 WO2002022080A2 (en) 2000-09-15 2001-09-14 Enhanced first generation adenovirus vaccines expressing codon optimized hiv1-gag, pol, nef and modifications

Publications (2)

Publication Number Publication Date
EP1320621A2 EP1320621A2 (en) 2003-06-25
EP1320621A4 true EP1320621A4 (en) 2005-11-23

Family

ID=22876220

Family Applications (1)

Application Number Title Priority Date Filing Date
EP01975214A Withdrawn EP1320621A4 (en) 2000-09-15 2001-09-14 IMPROVED ADENOVIRAL VACCINES OF THE FIRST GENERATION FOR THE EXPRESSION OF CODON-OPTIMIZED HIV-1 GAG, POL, NEF AND MODIFICATIONS (25.03.02)

Country Status (5)

Country Link
EP (1) EP1320621A4 (enExample)
JP (1) JP2004508064A (enExample)
AU (2) AU2001294562B2 (enExample)
CA (1) CA2422882A1 (enExample)
WO (1) WO2002022080A2 (enExample)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU782193B2 (en) * 1999-12-17 2005-07-07 Merck & Co., Inc. Polynucleotide vaccines expressing codon optimized HIV-1 Nef and modified HIV-1 Nef
JP4475561B2 (ja) 2001-10-11 2010-06-09 メルク・シャープ・エンド・ドーム・コーポレイション Ｃ型肝炎ウイルスワクチン
CN1606625A (zh) 2001-10-31 2005-04-13 南非医学研究会 Hiv－1亚型分离株调节/附加基因及其修饰物和衍生物
WO2003077859A2 (en) * 2002-03-13 2003-09-25 Merck & Co., Inc. Method of inducing an enhanced immune response against hiv
ATE386824T1 (de) 2002-03-29 2008-03-15 Merck & Co Inc Verfahren zur virusproduktion
EP1506287B1 (en) 2002-05-14 2007-04-25 Merck & Co., Inc. Methods of adenovirus purification
CN1490056A (zh) * 2002-10-18 2004-04-21 ��¡���ɵ°��̲��о����� 针对hiv-1的免疫方法和组合物
EP1553983A2 (en) 2002-10-23 2005-07-20 Crucell Holland B.V. New settings for recombinant adenoviral-based vaccines
US20080153083A1 (en) 2003-10-23 2008-06-26 Crucell Holland B.V. Settings for recombinant adenoviral-based vaccines
EP1573012B1 (en) 2002-12-17 2011-11-30 Crucell Holland B.V. Recombinant viral-based malaria vaccines
AU2003294023B2 (en) 2003-01-03 2008-01-31 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa Rhesus HER2/neu, nucleotides encoding same, and uses thereof
EP1649020B1 (en) 2003-07-21 2017-01-11 MSD Italia S.r.l. Synthetic gene encoding human epidermal growth factor 2/neu antigen and uses thereof
GB2406336A (en) * 2003-09-24 2005-03-30 Oxxon Pharmaccines Ltd HIV Pharmaccines
ATE555127T1 (de) 2004-02-11 2012-05-15 Angeletti P Ist Richerche Bio Fusionsproteine des karzinomembryonalen antigens und deren verwendungen
CN1922308A (zh) 2004-02-23 2007-02-28 克鲁塞尔荷兰公司 病毒纯化方法
WO2005110492A2 (en) * 2004-04-12 2005-11-24 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Method of using adenoviral vectors to induce an immune response
GB0417494D0 (en) 2004-08-05 2004-09-08 Glaxosmithkline Biolog Sa Vaccine
US7741099B2 (en) 2004-10-13 2010-06-22 Beth Israel Deaconess Medical Center Inc. Adenoviral vectors and uses thereof
ATE412737T1 (de) 2005-04-11 2008-11-15 Crucell Holland Bv Virusreinigung mit ultrafiltration
AU2012201827B2 (en) * 2005-05-12 2014-09-04 Glaxo Group Limited Vaccine composition
BRPI0608798A2 (pt) * 2005-05-12 2011-03-15 Glaxo Group Ltd vetor de adenovìrus, composição imunogênica, uso de um vetor de adenovìrus, método para preparar um vetor, uso de um vetor de vìrus e um carreador ou adjuvante farmaceuticamente aceitável, e, proteìna de fusão
EP1934246B8 (en) 2005-10-07 2012-02-08 Istituto di Ricerche di Biologia Molecolare P. Angeletti S.R.L. Matrix metalloproteinase 11 vaccine
US9717788B2 (en) 2007-03-02 2017-08-01 Glaxosmithkline Biologicals Sa Method of inducing an immune response against HIV employing HIV immunogens, adenoviral vectors encoding said immunogens, and adjuvant
CN103550764A (zh) * 2007-03-02 2014-02-05 葛兰素史密丝克莱恩生物有限公司 疫苗组合物及其在刺激免疫反应中的用途
ES2708856T3 (es) 2007-08-03 2019-04-11 Pasteur Institut Vectores de transferencia de gen lentivírico y sus aplicaciones medicinales
EP2047861B1 (en) * 2007-10-12 2019-07-31 Institut Pasteur Lentiviral gene transfer vectors suitable for iterative administration and their medicinal applications
WO2009022236A2 (en) 2007-08-16 2009-02-19 Tripep Ab Immunogen platform
PL2358757T3 (pl) * 2008-11-18 2019-02-28 Beth Israel Deaconess Medical Center Szczepionki antywirusowe o ulepszonej immunogenności komórkowej
ES2606511T3 (es) 2011-04-06 2017-03-24 Biovaxim Limited Composiciones farmacéuticas para prevenir y/o tratar una enfermedad por VIH en seres humanos
US8932607B2 (en) 2012-03-12 2015-01-13 Crucell Holland B.V. Batches of recombinant adenovirus with altered terminal ends
KR102044051B1 (ko) 2012-03-12 2019-11-12 얀센 백신스 앤드 프리벤션 비.브이. 터미널 말단이 변경된 재조합 아데노바이러스의 배치
CA2891349C (en) 2012-11-16 2023-07-18 Beth Israel Deaconess Medical Center, Inc. Recombinant adenoviruses and use thereof
EP3271729B1 (en) 2015-03-18 2020-09-23 Janssen Vaccines & Prevention B.V. Assays for recombinant expression systems
AU2016249798B2 (en) 2015-04-14 2022-05-26 Janssen Vaccines And Prevention B.V. Recombinant adenovirus expressing two transgenes with a bidirectional promoter
US11001858B2 (en) 2016-06-20 2021-05-11 Janssen Vaccines & Prevention B.V. Potent and balanced bidirectional promoter
SG11202003399TA (en) 2017-10-31 2020-05-28 Janssen Vaccines & Prevention Bv Adenovirus and uses thereof
MX421606B (es) 2017-10-31 2025-03-14 Janssen Vaccines & Prevention Bv Vectores adenovirales y usos de estos
WO2019086450A1 (en) 2017-10-31 2019-05-09 Janssen Vaccines & Prevention B.V. Adenovirus and uses thereof
MX2020004488A (es) 2017-10-31 2020-08-13 Janssen Vaccines & Prevention Bv Adenovirus y usos de estos.
WO2019118480A1 (en) 2017-12-11 2019-06-20 Beth Israel Deaconess Medical Center, Inc. Recombinant adenoviruses and uses thereof
CN111057716B (zh) * 2019-07-27 2022-04-15 中国人民解放军军事科学院军事医学研究院 用于包装重组人4型腺病毒的单质粒载体系统及其应用
CA3156471A1 (en) 2019-10-03 2021-04-08 Janssen Vaccines & Prevention B.V. Adenovirus vectors and uses thereof
CN112522276B (zh) * 2020-12-15 2022-07-15 武汉纽福斯生物科技有限公司 一种emc1核苷酸序列及其应用
WO2025242657A1 (en) 2024-05-21 2025-11-27 Shape Biopharmaceuticals Ag Lipopeptide building blocks and aggregates
CN118931872B (zh) * 2024-10-14 2025-05-20 南京诺唯赞生物科技股份有限公司 Rna聚合酶变体及其应用

Citations (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996009399A2 (en) * 1994-09-23 1996-03-28 Somatix Therapy Corporation Chimeric adenovirus for gene delivery
WO1996014061A1 (en) * 1994-11-03 1996-05-17 Cell Genesys, Inc. Novel adenoviral vectors, packaging cell lines, recombinant adenoviruses and methods
WO1999002647A2 (de) * 1997-07-10 1999-01-21 Hepavec Ag Für Gentherapie Klonierungsvektoren für die herstellung von adenoviralen minimalviren
WO1999041397A1 (en) * 1998-02-17 1999-08-19 Oxford Biomedica (Uk) Limited Anti-viral vectors
WO1999055132A2 (en) * 1998-04-24 1999-11-04 Introgene B.V. Generation of packaging system for human recombinant adenoviral vectors
US6040174A (en) * 1993-05-28 2000-03-21 Transgene S.A. Defective adenoviruses and corresponding complementation lines
WO2000015819A1 (en) * 1998-09-11 2000-03-23 The Children's Medical Center Corporation Packaging cell lines for hiv-derived retroviral vector particles
WO2000039302A2 (en) * 1998-12-31 2000-07-06 Chiron Corporation Improved expression of hiv polypeptides and production of virus-like particles
WO2000055341A1 (en) * 1999-03-17 2000-09-21 Oxford Biomedica (Uk) Limited Anti-viral vectors
WO2000075370A1 (en) * 1999-06-03 2000-12-14 Oxford Biomedica (Uk) Limited In vivo selection method for determining inhibitory rna molecules
WO2001045748A1 (en) * 1999-12-22 2001-06-28 Merck & Co., Inc. Polynucleotide vaccines expressing codon optimized hiv-1 pol and modified hiv-1 pol
EP1156112A1 (en) * 2000-05-18 2001-11-21 Geneart GmbH Synthetic gagpol genes and their uses
WO2002032943A2 (en) * 2000-08-14 2002-04-25 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Modifications of hiv env, gag, and pol enhance immunogenicity for genetic immunization

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5643579A (en) * 1984-11-01 1997-07-01 American Home Products Corporation Oral vaccines
US6019978A (en) * 1995-06-05 2000-02-01 The Wistar Institute Of Anatomy And Biology Replication-defective adenovirus human type 5 recombinant as a vaccine carrier
WO1996039178A1 (en) * 1995-06-05 1996-12-12 The Wistar Institute Of Anatomy And Biology A replication-defective adenovirus human type 5 recombinant as a vaccine carrier

Patent Citations (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6040174A (en) * 1993-05-28 2000-03-21 Transgene S.A. Defective adenoviruses and corresponding complementation lines
WO1996009399A2 (en) * 1994-09-23 1996-03-28 Somatix Therapy Corporation Chimeric adenovirus for gene delivery
WO1996014061A1 (en) * 1994-11-03 1996-05-17 Cell Genesys, Inc. Novel adenoviral vectors, packaging cell lines, recombinant adenoviruses and methods
WO1999002647A2 (de) * 1997-07-10 1999-01-21 Hepavec Ag Für Gentherapie Klonierungsvektoren für die herstellung von adenoviralen minimalviren
WO1999041397A1 (en) * 1998-02-17 1999-08-19 Oxford Biomedica (Uk) Limited Anti-viral vectors
WO1999055132A2 (en) * 1998-04-24 1999-11-04 Introgene B.V. Generation of packaging system for human recombinant adenoviral vectors
WO2000015819A1 (en) * 1998-09-11 2000-03-23 The Children's Medical Center Corporation Packaging cell lines for hiv-derived retroviral vector particles
WO2000039302A2 (en) * 1998-12-31 2000-07-06 Chiron Corporation Improved expression of hiv polypeptides and production of virus-like particles
WO2000055341A1 (en) * 1999-03-17 2000-09-21 Oxford Biomedica (Uk) Limited Anti-viral vectors
WO2000075370A1 (en) * 1999-06-03 2000-12-14 Oxford Biomedica (Uk) Limited In vivo selection method for determining inhibitory rna molecules
WO2001045748A1 (en) * 1999-12-22 2001-06-28 Merck & Co., Inc. Polynucleotide vaccines expressing codon optimized hiv-1 pol and modified hiv-1 pol
EP1156112A1 (en) * 2000-05-18 2001-11-21 Geneart GmbH Synthetic gagpol genes and their uses
WO2002032943A2 (en) * 2000-08-14 2002-04-25 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Modifications of hiv env, gag, and pol enhance immunogenicity for genetic immunization

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
ANDRE S ET AL: "INCREASED IMMUNE RESPONSE ELICITED BY DNA VACCINATION WITH A SYNTHETIC GP120 SEQUENCE WITH OPTIMIZED CODON USAGE", JOURNAL OF VIROLOGY, THE AMERICAN SOCIETY FOR MICROBIOLOGY, US, vol. 72, no. 2, February 1998 (1998-02-01), pages 1497 - 1503, XP002073767, ISSN: 0022-538X *
BRUCE ET AL: "Replication-deficient recombinant adenoviruses expressing the human immunodeficiency virus ENV antigen can induce both humoral and CTL immune responses in mice", JOURNAL OF GENERAL VIROLOGY, vol. 80, 1999, pages 2621 - 2628, XP002963542 *
HU Y-W ET AL: "ENZYME ACTIVITIES IN FOUR DIFFERENT FORMS OF HUMAN IMMUNODEFICIENCY VIRUS 1 POL GENE PRODUCTS", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, vol. 88, no. 11, 1991, pages 4596 - 4600, XP002306309, ISSN: 0027-8424 *
JOSHI S ET AL: "Molecular biology of human immunodeficiency virus Type-1", TRANSFUSION SCIENCE, PERGAMON PRESS, OXFORD, GB, vol. 17, no. 3, September 1996 (1996-09-01), pages 351 - 378, XP004568809, ISSN: 0955-3886 *
KARACOSTAS VELISSARIOS ET AL: "Overexpression of the HIV-1 Gag-Pol polyprotein results in intracellular activation of HIV-1 protease and inhibition of assembly and budding of virus-like particles", VIROLOGY, vol. 193, no. 2, 1993, pages 661 - 671, XP002306310, ISSN: 0042-6822 *
MIYAKE KOICHI ET AL: "A new strategy for large scale preparation of high-titer HIV vectors using adenovirus-based expression vectors", BLOOD, vol. 96, 16 November 2000 (2000-11-16), pages 430A *

Also Published As

Publication number Publication date
WO2002022080A3 (en) 2002-05-02
EP1320621A2 (en) 2003-06-25
WO2002022080A9 (en) 2003-03-06
AU9456201A (en) 2002-03-26
WO2002022080A2 (en) 2002-03-21
CA2422882A1 (en) 2002-03-21
WO2002022080A8 (en) 2003-01-16
AU2001294562B2 (en) 2007-05-24
AU2001294562B8 (en) 2002-03-26
JP2004508064A (ja) 2004-03-18

Similar Documents

Publication Publication Date Title
AU8499901A (en) Modifications of hiv env, gag, and pol enhance immunogenicity for genetic immunization
WO2001064710A8 (en) Sulfated ccr5 peptides for hiv-1 infection
NO20041157L (no) HIV-GAG kodonoptimaliserte DNA-vaksiner
NO20032893D0 (no) Urtepreparat for angina pectoris, fremstilling og anvendelse derav
DE60101793D1 (de) Hitzebeständige materialien
NO20004413D0 (no) HIV peptider, antigener, vaksine, blandinger, immunoassay, kit og en fremgangmÕte for pÕvisning av antistoffer som blir infusert av HIV
AU9456201A (en) Enhanced first generation adenovirus vaccines expressing codon optimized hiv1-gag, pol, nef and modifications
CY2013025I2 (el) Ετερολογος εκφραση των πρωτεϊνων της neisseria
IL150961A0 (en) Human immunodeficiency virus vaccine
HUP0204250A1 (hu) HIV-protein vagy- polinukleotid alkalmazása vakcina előállítására
IL202249A (en) Nucleic Acids Encoders Human Immunodeficiency Strange Type 1 (HIV – 1) Group M Consensus Envelope Glycoproteins
DK1210113T3 (da) Kombinerede vaccinepræparater
NO20030713L (no) Oral faststoffdose vaksine
BR0101471B1 (pt) aplicador dental descartável.
NO20030111D0 (no) Kjemokinreseptor-modulatorer, deres fremstilling og anvendelse
DK1328547T3 (da) Identifikation og modifikation af immundominante epitoper i polypeptider
WO2002004007A3 (en) Stable (fixed) forms of viral capsid proteins, fusion proteins and uses thereof
TW200502245A (en) Vaccine
EP1242124A4 (en) POLYNUCLEOTIDE VACCINES EXPRESSING CODONE-OPTIMIZED HIV-1 POL AND MODIFIED HIV-1 POL
EP2567967A3 (en) Method of using adenoviral vectors to induce an immune response
DE60105369D1 (de) Wegwerfhöschen
FR2806912B1 (fr) UTILISATION DE PROTEINES gp120 ET gp160 MODIFIEES DANS LA BOUCLE V3 DU VIH-1 POUR LA PREPARATION DE COMPOSITIONS VACCINALES ET FORMULATIONS LES CONTENANT
WO2002012539A3 (en) Nucleic acid constructs, vascular cells transformed therewith, pharmaceutical compositions and methods utilizing same for inducing angiogenesis
DE60125927D1 (de) Impfstoffe gegen hiv
EP1802332A4 (en) MODIFIED HIV-1 CREAM PROTEINS

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20030415

AK Designated contracting states

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

AX Request for extension of the european patent

Extension state: AL LT LV MK RO SI

RIN1 Information on inventor provided before grant (corrected)

Inventor name: CASIMIRO, DANILO, R.

Inventor name: TONER, TIMOTHY, J.

Inventor name: SHIVER, JOHN, W.

Inventor name: KASLOW, DAVID, C.

Inventor name: CHEN, LING

Inventor name: BETT, ANDREW, J.

Inventor name: YOUIL, RIMA

Inventor name: EMINI, EMILIO, A.

A4 Supplementary search report drawn up and despatched

Effective date: 20051007

17Q First examination report despatched

Effective date: 20061017

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20080805